Dry Age Related Macular Degeneration (AMD) Global Market Report 2025
상품코드:1826919
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
건성 노인황반변성 시장 규모는 최근 몇 년 동안 강력하게 성장하고 있습니다. 2024년 44억 9,000만 달러에서 2025년에는 48억 9,000만 달러까지 CAGR 8.8%를 나타낼 전망입니다. 성과기간 성장은 고령화 인구 증가, 만성질환 유병률 증가, 눈 건강에 대한 의식 증가, 건성 노인황반변성(AMD)에 초점을 맞춘 임상시험 증가, 낮은 침습 치료에 대한 수요 증가로 인한 것입니다.
건성 노인황반변성 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 8.6%를 나타내 68억 달러로 성장할 전망입니다. 예측기간의 성장은 새로운 치료법의 출현, 헬스케어 지출 증가, 레이저 광응고요법의 이용률 상승, 유전자 연구의 진보, 맞춤형 의료에 대한 주목 증가 등에 기인하고 있습니다. 예측기간의 주요 동향에는 진단기술의 진보, 원격안과의 채용 증가, 기술적으로 진보된 치료, 제품 승인, 신제품의 출시 등이 포함됩니다.
건성 노인황반변성은 진행성 안질환으로 망막의 중심부인 황반이 서서히 악화되어 중심 시력이 흐려집니다. 비타민, 영양 보충제 및 새로운 약물 요법을 포함한 치료 옵션은 질병 진행을 관리하고 지연시키는 것을 목표로 합니다.
건성 노인황반변성의 주요 병기는 조기 연령 황반 변성, 중기 연령 황반 변성, 후기 연령 황반 변성입니다. 조기 AMD는이 일반적인 안구 질환의 초기 단계이며 주로 노인이 앓고 망막, 특히 중심 시력을 담당하는 황반에 변화를 일으 킵니다. 40세 이상, 60세 이상, 75세 이상 등 다양한 연령층에서 발병합니다. 치료는 경구제나 주사제 등 다양한 경로로 이루어져 병원, 진료소, 진단센터, 학술·연구 기관 등 다양한 최종 사용자에 의해 이용되고 있습니다.
2025년 봄 미국 관세의 급상승과 이에 따른 무역 마찰은 의료 분야, 특히 필수적인 의료기기, 진단 장비 및 의약품 공급에 큰 영향을 미쳤습니다. 병원과 건강 관리 제공업체는 수입되는 수술 기구, 영상 진단 시스템, 주사기 및 카테터와 같은 소모품의 비용 상승에 시달리고 있으며, 그 대부분은 국내 대체품이 제한되어 있습니다. 이러한 비용 상승이 의료 예산을 압박하기 때문에 일부 의료기관은 장비 업그레이드를 늦추거나 비용 증가를 환자에게 전가하고 있습니다. 게다가 원료와 부품에 대한 관세는 중요한 의약품과 의료기기의 제조에 지장을 주고 공급망의 지연으로 이어지고 있습니다. 이에 비해 업계는 다양한 조달 전략을 채택하고 가능한 한 현지 생산을 확대하고 중요한 의료 제품의 관세 면제를 수행하고 있습니다.
이 조사 보고서는 건성 노인황반변성 업계 세계 시장 규모, 지역 점유율, 건성 노인황반변성 시장 점유율을 가진 경쟁 업체, 상세한 건성 노인황반변성 시장 부문, 시장 동향 및 비즈니스 기회, 건성 노인황반변성 업계에서 성공하는 데 필요한 데이터 등 건성 노인황반변성 시장 통계를 제공합니다. Business Research Company의 신간 보고서 시리즈 중 하나입니다. 이 건성 노인황반변성 시장 조사 보고서는 업계의 현재 및 미래 시나리오를 자세히 분석하고 필요한 모든 것을 완벽한 관점에서 제공합니다.
향후 5년간의 성장률 8.6%라고 하는 예측은 전회의 예측으로부터 0.2%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 마찰은 벨기에와 일본에서 수입되는 보체 억제제 및 망막 영상 진단 장치의 가격을 늘리고 노인 환자의 시력 저하를 가속화할 수 있으므로 치료 옵션을 좁힐 수 있습니다. 또한 상호 관세와 무역 긴장 증가와 제한으로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향이 더 광범위하게 늘어날 것으로 보입니다.
노년 인구 증가는 건성 노인황반변성 시장 성장을 이끌 것으로 예측됩니다. 노년 인구는 노인을 말하며 일반적으로 65세 이상의 개인으로 정의됩니다. 이 인구층 증가는 의료 기술의 진보, 만성 질환 관리의 향상, 평균 수명의 연장, 노인 의료의 개선에 의해 야기됩니다. 건성 노인황반변성은 질병의 진행을 늦추고 시력을 유지하고 고령자의 삶의 질을 높이는 것을 목적으로 하는 치밀한 치료와 관리 방법을 제공함으로써 고령화 사회를 지원하는 중요한 역할을 담당하고 있습니다. 예를 들어 2024년 6월 미국에 본사를 둔 단체인 National Council on Aging의 보고에 따르면 2022년에는 65세 이상의 성인이 약 5,780만명으로 미국 총인구의 17.3%를 차지했고 2021년의 16.9%에서 증가했습니다. 그 결과 노인 인구 증가가 건성 노인황반변성 시장 확대에 박차를 가할 것으로 예측됩니다.
건성 노인황반변성 시장 주요 기업은 망막 세포를 표적으로 활성화하고 질병의 진행을 지연시킬 수 있는 광 전달 시스템과 같은 첨단 기술과 치료법의 개발에 주력하고 있습니다. 광전송 시스템은 특히 치료 용도로 빛을 전달하도록 설계되었습니다. 예를 들어, 2024년 1월 미국 의료기기 회사 LumiThera Inc.는 Valeda Light Delivery System에 의한 드라이 AMD의 광 바이오 모듈레이션(PBM) 요법을 발표했습니다. 이것은 치료 옵션이 제한된 드라이 AMD 환자의 시력 저하를 다루는 것을 목표로 한 최초의 FDA 승인 치료입니다. 루미셀라는 또한 Valeda 시스템의 결과에 대한 장기적인 환자 데이터를 수집하는 EUROLIGHT 레지스트리 연구를 시작했습니다. Valeda 시스템은 3개의 특정 파장(590nm, 660nm, 850nm)을 가진 다파장 광 조사 방식을 채용하고 있습니다. 이 비침습적인 치료는 눈꺼풀을 열린 상태 또는 닫힌 상태에서 수행할 수 있으며 일반적으로 3-4주에 걸쳐 9회의 세션이 필요합니다.
2023년 5월 일본 제약회사인 아스텔라스 제약은 IVERIC Bio Inc.를 59억 달러로 인수했습니다. 이 인수는 안과 시장에서 아스텔라스 제약의 존재를 강화하고 망막 질환에 대한 혁신적인 치료법의 개발을 가속화하고 세계 환자의 결과를 개선합니다. IVERIC Bio Inc.는 미국의 생명 공학 기업으로 노인황반변성 치료 및 관련 치료제의 개발을 전문으로 하며, 아스텔라스 제약의 이 분야에서 R&D를 더욱 강화합니다.
건성 노인황반변성 시장은 syfovre, zimura, visudyne, alk-001의 판매로 구성됩니다. 이 시장의 가치는 "Factory Gate"의 가치입니다. 즉, 제품의 제조자 또는 창조자가 다른 기업(다운스트림 제조자, 도매업체, 유통업체, 소매업체 포함) 또는 직접 최종 고객에게 판매한 상품의 가치입니다. 이 시장에서 상품의 가치에는 상품 제작자에 의해 판매되는 관련 서비스도 포함됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 건성 노인황반변성 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 건성 노인황반변성 시장 : 성장률 분석
세계의 건성 노인황반변성 시장 실적 : 규모와 성장(2019-2024년)
세계의 건성 노인황반변성 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 건성 노화황반변성 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 건성 노인황반변성 시장 : 단계별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
조기 노인황반변성
중기 노인황반변성
후기 노인황반변성
세계의 건성 노인황반변성 시장 : 연령층별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
75세 이상
60세 이상
40세 이상
세계의 건성 노인황반변성 시장 : 투여 경로, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
주사제
세계의 건성 노인황반변성 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 및 진료소
진단 센터
학술 및 연구 기관
세계의 건성 노인황반변성 시장 : 조기 노인황반변성 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
드루젠 축적
망막색소상피 변화
세계의 건성 노인황반변성 시장 : 중기 노인황반변성 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
대형 드루젠 침착
색소 이상 증가
세계의 건성 노인황반변성 시장 : 후기 노인황반변성 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
지리적 위축
중심 시력 상실
제7장 지역별/국가별 분석
세계의 건성 노인황반변성 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 건성 노인황반변성 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
건성 노인황반변성 시장 : 경쟁 구도
건성 노인황반변성 시장 : 기업 프로파일
F Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Amgen Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Biogen Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Astellas Pharma Inc.
Bausch Health Companies Inc.
Lupin Ltd.
Santen Pharmaceuticals Inc.
Biocon Ltd.
Alimera Sciences Inc.
Apellis Pharmaceuticals Inc.
Belite Bio Inc.
Axol Bioscience Ltd.
Alkeus Pharmaceuticals Inc.
Kubota Holdings Co.
Ribomic Inc.
Eyestem Research Pvt. Ltd.
LumiThera Inc.
Adverum Biotechnologies Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
건성 노인황반변성 시장(2029년) : 새로운 기회를 제공하는 국가
건성 노인황반변성 시장(2029년) : 새로운 기회를 제공하는 부문
건성 노인황반변성 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Dry age-related macular degeneration (AMD) is a progressive eye condition that involves the gradual deterioration of the macula, the central part of the retina, leading to blurred central vision. Treatment options, including vitamins, nutritional supplements, and emerging pharmaceutical therapies, aim to manage and slow the disease's progression.
The main stages of dry AMD are early age-related macular degeneration, intermediate age-related macular degeneration, and late age-related macular degeneration. Early AMD is the initial stage of this common eye condition, which primarily affects older adults and causes changes in the retina, specifically the macula, responsible for central vision. It affects various age groups, including those above 40, 60, and 75 years. Treatment is administered through different routes, such as oral and injectable forms, and is utilized by various end users, including hospitals, clinics, diagnostic centers, and academic and research institutes.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The dry age related macular degeneration (AMD) market research report is one of a series of new reports from The Business Research Company that provides dry age related macular degeneration (AMD) market statistics, including dry age related macular degeneration (AMD) industry global market size, regional shares, competitors with a dry age related macular degeneration (AMD) market share, detailed dry age related macular degeneration (AMD) market segments, market trends and opportunities, and any further data you may need to thrive in the dry age related macular degeneration (AMD) industry. This dry age related macular degeneration (AMD) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The dry age related macular degeneration (amd) market size has grown strongly in recent years. It will grow from $4.49 billion in 2024 to $4.89 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to a rising aging population, increased prevalence of chronic diseases, rising awareness of eye health, a growing number of clinical trials focusing on dry AMD, and growing demand for minimally invasive treatments.
The dry age related macular degeneration (amd) market size is expected to see strong growth in the next few years. It will grow to $6.8 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to emerging novel therapies, increasing healthcare expenditure, rising utilization of laser photocoagulation therapy, advancements in genetic research, and a growing focus on personalized medicine. Major trends in the forecast period include advancements in diagnostic technologies, rising adoption of teleophthalmology, technologically advanced treatments, product approvals, and new product launches.
The forecast of 8.6% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could limit treatment options by inflating prices of complement inhibitor drugs and retinal imaging devices imported from Belgium and Japan, potentially accelerating vision loss in elderly patients. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing geriatric population is expected to drive the growth of the dry age-related macular degeneration (AMD) market. The geriatric population refers to older adults, typically defined as individuals aged 65 and older. The rise in this demographic is driven by advancements in medical technology, better management of chronic diseases, increased life expectancy, and improved geriatric care. Dry AMD plays a crucial role in supporting the aging population by providing targeted treatments and management options aimed at slowing disease progression, preserving vision, and enhancing the quality of life for older individuals affected by the condition. For example, in June 2024, a report by the National Council on Aging, a US-based organization, stated that in 2022, there were approximately 57.8 million adults aged 65 and older, making up 17.3% of the total U.S. population, an increase from 16.9% in 2021. As a result, the growing geriatric population is expected to fuel the expansion of the dry AMD market.
Leading companies in the dry AMD market are focusing on developing advanced technologies and treatments, such as light delivery systems, to target and activate retinal cells, potentially slowing disease progression. Light delivery systems are designed to transmit light for therapeutic applications, particularly in medical treatments. For instance, in January 2024, LumiThera Inc., a US-based medical device company, introduced photobiomodulation (PBM) therapy for dry AMD through the Valeda Light Delivery System. This is the first FDA-authorized therapy aimed at addressing vision loss in patients with dry AMD, a condition with limited treatment options. LumiThera also launched the EUROLIGHT registry study to collect long-term patient data on Valeda system outcomes. The Valeda system uses a multi-wavelength light delivery method with three specific wavelengths (590 nm, 660 nm, and 850 nm). This non-invasive treatment can be administered through an open or closed eyelid and typically requires nine sessions over three to four weeks.
In May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc. for $5.9 billion. This acquisition strengthens Astellas Pharma's presence in the ophthalmology market and accelerates the development of innovative treatments for retinal diseases, improving patient outcomes worldwide. IVERIC Bio Inc., a US-based biotech company, specializes in the development of age-related macular degeneration drugs and related treatments, further enhancing Astellas Pharma's research and development capabilities in the field.
Major players in the dry age related macular degeneration (AMD) market are F Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Amgen Inc., Biogen Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Lupin Ltd., Santen Pharmaceuticals Inc., Biocon Ltd., Alimera Sciences Inc., Apellis Pharmaceuticals Inc., Belite Bio Inc., Axol Bioscience Ltd., Alkeus Pharmaceuticals Inc., Kubota Holdings Co., Ribomic Inc., Eyestem Research Pvt. Ltd., LumiThera Inc., Adverum Biotechnologies Inc.
North America was the largest region in the dry age-related macular degeneration (AMD) market in 2024. The regions covered in dry age-related macular degeneration (AMD) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the dry age related macular degeneration (AMD) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dry age related macular degeneration (AMD) market consists of sales of syfovre, zimura, visudyne, and alk-001. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Dry Age Related Macular Degeneration (AMD) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on dry age related macular degeneration (amd) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for dry age related macular degeneration (amd) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The dry age related macular degeneration (amd) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Stages: Early Age-Related Macular Degeneration; Intermediate Age-Related Macular Degeneration; Late Age-Related Macular Degeneration
2) By Age Group: Above 75 Years; Above 60 Years; Above 40 Years
3) By Route Of Administration: Oral; Injectables
4) By End Users: Hospitals And Clinics; Diagnostic Centers; Academic And Research Institutes
Subsegments:
1) By Early Age-Related Macular Degeneration: Drusen Accumulation; Retinal Pigment Epithelium Changes
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Dry Age Related Macular Degeneration (AMD) Market Characteristics
3. Dry Age Related Macular Degeneration (AMD) Market Trends And Strategies
4. Dry Age Related Macular Degeneration (AMD) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Dry Age Related Macular Degeneration (AMD) Growth Analysis And Strategic Analysis Framework
5.1. Global Dry Age Related Macular Degeneration (AMD) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Dry Age Related Macular Degeneration (AMD) Market Growth Rate Analysis
5.4. Global Dry Age Related Macular Degeneration (AMD) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Dry Age Related Macular Degeneration (AMD) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Dry Age Related Macular Degeneration (AMD) Total Addressable Market (TAM)
6. Dry Age Related Macular Degeneration (AMD) Market Segmentation
6.1. Global Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Early Age-Related Macular Degeneration
Intermediate Age-Related Macular Degeneration
Late Age-Related Macular Degeneration
6.2. Global Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Above 75 Years
Above 60 Years
Above 40 Years
6.3. Global Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectables
6.4. Global Dry Age Related Macular Degeneration (AMD) Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Diagnostic Centers
Academic And Research Institutes
6.5. Global Dry Age Related Macular Degeneration (AMD) Market, Sub-Segmentation Of Early Age-Related Macular Degeneration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Drusen Accumulation
Retinal Pigment Epithelium Changes
6.6. Global Dry Age Related Macular Degeneration (AMD) Market, Sub-Segmentation Of Intermediate Age-Related Macular Degeneration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Larger Drusen Deposits
Increased Pigmentary Abnormalities
6.7. Global Dry Age Related Macular Degeneration (AMD) Market, Sub-Segmentation Of Late Age-Related Macular Degeneration, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Geographic Atrophy
Central Vision Loss
7. Dry Age Related Macular Degeneration (AMD) Market Regional And Country Analysis
7.1. Global Dry Age Related Macular Degeneration (AMD) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Dry Age Related Macular Degeneration (AMD) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Dry Age Related Macular Degeneration (AMD) Market
8.1. Asia-Pacific Dry Age Related Macular Degeneration (AMD) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Dry Age Related Macular Degeneration (AMD) Market
9.1. China Dry Age Related Macular Degeneration (AMD) Market Overview
9.2. China Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Dry Age Related Macular Degeneration (AMD) Market
10.1. India Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Dry Age Related Macular Degeneration (AMD) Market
11.1. Japan Dry Age Related Macular Degeneration (AMD) Market Overview
11.2. Japan Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Dry Age Related Macular Degeneration (AMD) Market
12.1. Australia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Dry Age Related Macular Degeneration (AMD) Market
13.1. Indonesia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Dry Age Related Macular Degeneration (AMD) Market
14.1. South Korea Dry Age Related Macular Degeneration (AMD) Market Overview
14.2. South Korea Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Dry Age Related Macular Degeneration (AMD) Market
15.1. Western Europe Dry Age Related Macular Degeneration (AMD) Market Overview
15.2. Western Europe Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Dry Age Related Macular Degeneration (AMD) Market
16.1. UK Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Dry Age Related Macular Degeneration (AMD) Market
17.1. Germany Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Dry Age Related Macular Degeneration (AMD) Market
18.1. France Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Dry Age Related Macular Degeneration (AMD) Market
19.1. Italy Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Dry Age Related Macular Degeneration (AMD) Market
20.1. Spain Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Dry Age Related Macular Degeneration (AMD) Market
21.1. Eastern Europe Dry Age Related Macular Degeneration (AMD) Market Overview
21.2. Eastern Europe Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Dry Age Related Macular Degeneration (AMD) Market
22.1. Russia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Dry Age Related Macular Degeneration (AMD) Market
23.1. North America Dry Age Related Macular Degeneration (AMD) Market Overview
23.2. North America Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Dry Age Related Macular Degeneration (AMD) Market
24.1. USA Dry Age Related Macular Degeneration (AMD) Market Overview
24.2. USA Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Dry Age Related Macular Degeneration (AMD) Market
25.1. Canada Dry Age Related Macular Degeneration (AMD) Market Overview
25.2. Canada Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Dry Age Related Macular Degeneration (AMD) Market
26.1. South America Dry Age Related Macular Degeneration (AMD) Market Overview
26.2. South America Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Dry Age Related Macular Degeneration (AMD) Market
27.1. Brazil Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Dry Age Related Macular Degeneration (AMD) Market
28.1. Middle East Dry Age Related Macular Degeneration (AMD) Market Overview
28.2. Middle East Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Dry Age Related Macular Degeneration (AMD) Market
29.1. Africa Dry Age Related Macular Degeneration (AMD) Market Overview
29.2. Africa Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Dry Age Related Macular Degeneration (AMD) Market, Segmentation By Route Of Admininstration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Dry Age Related Macular Degeneration (AMD) Market Competitive Landscape And Company Profiles
30.1. Dry Age Related Macular Degeneration (AMD) Market Competitive Landscape
30.2. Dry Age Related Macular Degeneration (AMD) Market Company Profiles
30.2.1. F Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Dry Age Related Macular Degeneration (AMD) Market Other Major And Innovative Companies
31.1. Astellas Pharma Inc.
31.2. Bausch Health Companies Inc.
31.3. Lupin Ltd.
31.4. Santen Pharmaceuticals Inc.
31.5. Biocon Ltd.
31.6. Alimera Sciences Inc.
31.7. Apellis Pharmaceuticals Inc.
31.8. Belite Bio Inc.
31.9. Axol Bioscience Ltd.
31.10. Alkeus Pharmaceuticals Inc.
31.11. Kubota Holdings Co.
31.12. Ribomic Inc.
31.13. Eyestem Research Pvt. Ltd.
31.14. LumiThera Inc.
31.15. Adverum Biotechnologies Inc.
32. Global Dry Age Related Macular Degeneration (AMD) Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Dry Age Related Macular Degeneration (AMD) Market
34. Recent Developments In The Dry Age Related Macular Degeneration (AMD) Market
35. Dry Age Related Macular Degeneration (AMD) Market High Potential Countries, Segments and Strategies
35.1 Dry Age Related Macular Degeneration (AMD) Market In 2029 - Countries Offering Most New Opportunities
35.2 Dry Age Related Macular Degeneration (AMD) Market In 2029 - Segments Offering Most New Opportunities
35.3 Dry Age Related Macular Degeneration (AMD) Market In 2029 - Growth Strategies
